Selenium in the Treatment of Head and Neck Lymphedema

Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were tre...

Full description

Saved in:
Bibliographic Details
Published inMedical principles and practice Vol. 13; no. 4; pp. 185 - 190
Main Authors Bruns, F., Büntzel, J., Mücke, R., Schönekaes, K., Kisters, K., Micke, O.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland 01.01.2004
Subjects
Online AccessGet full text
ISSN1011-7571
1423-0151
1423-0151
DOI10.1159/000078313

Cover

Abstract Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m 2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
AbstractList To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium. 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m 2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.OBJECTIVETo investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery.Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium.SUBJECTS AND MATERIALSBetween June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 microg/m(2) body surface sodium selenite medication p.o. daily (total dose 50 microg per day) for a period of 4-6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0-10 was used to assess the patient's quality of life prior to and after selenium.75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients.RESULTS75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients.Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.CONCLUSIONOur results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
Author Büntzel, J.
Micke, O.
Kisters, K.
Schönekaes, K.
Mücke, R.
Bruns, F.
Author_xml – sequence: 1
  givenname: F.
  surname: Bruns
  fullname: Bruns, F.
– sequence: 2
  givenname: J.
  surname: Büntzel
  fullname: Büntzel, J.
– sequence: 3
  givenname: R.
  surname: Mücke
  fullname: Mücke, R.
– sequence: 4
  givenname: K.
  surname: Schönekaes
  fullname: Schönekaes, K.
– sequence: 5
  givenname: K.
  surname: Kisters
  fullname: Kisters, K.
– sequence: 6
  givenname: O.
  surname: Micke
  fullname: Micke, O.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15181321$$D View this record in MEDLINE/PubMed
BookMark eNp90N9LwzAQB_AgE_dDH3wWpPggKNTleu3WPMpQJ0wdOJ9Lml5dXZvWtEX239vZMUGGeUkgn_teLn3W0bkmxk6B3wB4YsibNfYR8ID1wHXQ5uBBpzlzAHvsjaHL-mX50SgfkR-xbnPtAzrQY94rpaSTOrMSbVVLshaGZJWRrqw8tqYkI0vqyHomtbJm66xYUkSZPGaHsUxLOtnuA_Z2f7eYTO3Zy8Pj5HZmKxxhZTsYqpB7gmOMRD5GkeLhyOeIftw8jfsOkRi5ygPlhEQjBJcUCfJBuUrEDg7YdZtb60Kuv2SaBoVJMmnWAfBgM3uwm73Bly0uTP5ZU1kFWVIqSlOpKa_LYAxCCBSb1PMtrMOMot_I7a804KoFyuRlaSj-t-vwj1VJJask15WRSbq34qKtWEnzTmaX_TSf_4CgiOIGne1FbcQ3fXqR5w
CitedBy_id crossref_primary_10_1016_j_oraloncology_2015_01_005
crossref_primary_10_1093_jncimonographs_lgz005
crossref_primary_10_1111_ecc_12894
crossref_primary_10_1055_a_1746_1932
crossref_primary_10_12968_bjcn_2021_26_Sup4_S24
crossref_primary_10_1089_ars_2010_3275
crossref_primary_10_3390_nu11051021
crossref_primary_10_1089_lrb_2004_2_183
crossref_primary_10_1016_j_ijrobp_2012_04_013
crossref_primary_10_1097_MD_0000000000030910
crossref_primary_10_1017_S1446545000000026
crossref_primary_10_1089_jpm_2016_0174
crossref_primary_10_1055_a_1558_5820
crossref_primary_10_1089_lrb_2004_2_147
crossref_primary_10_1007_s00129_007_2056_x
crossref_primary_10_1590_0103_5150_029_002_AO20
crossref_primary_10_1001_jamaoto_2023_1473
crossref_primary_10_1002_hed_27136
crossref_primary_10_1016_j_hoc_2008_04_012
crossref_primary_10_1055_s_0042_1745726
crossref_primary_10_3390_nu13093253
crossref_primary_10_1055_a_1263_2976
crossref_primary_10_1188_11_ONF_E1_E10
crossref_primary_10_3109_13880209_2012_749923
crossref_primary_10_1080_09638288_2024_2366004
crossref_primary_10_1371_journal_pone_0026259
crossref_primary_10_1007_s11764_023_01453_7
crossref_primary_10_1007_s00761_007_1199_7
crossref_primary_10_1089_ars_2009_2884
crossref_primary_10_1007_s40268_021_00340_9
crossref_primary_10_1055_a_1545_2202
crossref_primary_10_1002_hed_23084
crossref_primary_10_1016_j_bjps_2006_04_013
crossref_primary_10_1016_j_amjoto_2019_05_024
crossref_primary_10_1055_a_1837_4511
crossref_primary_10_1089_lrb_2017_0074
crossref_primary_10_1007_s00520_011_1294_6
crossref_primary_10_1007_s00761_013_2461_9
crossref_primary_10_1007_s13126_020_0548_5
crossref_primary_10_1188_13_ONF_501_506
crossref_primary_10_3390_molecules14103975
crossref_primary_10_1002_hed_21001
crossref_primary_10_1007_s15013_016_1000_3
crossref_primary_10_3892_mco_2018_1663
Cites_doi 10.1007/s001060050303
10.1016/S0140-6736(00)02490-9
10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M
10.1016/0360-3016(95)00057-6
10.1016/S0002-9343(00)00727-0
10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0
10.1385/BTER:73:2:97
10.1046/j.1524-4741.2000.99072.x
10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3
10.1056/NEJM199310143291604
10.1097/00002060-200110000-00001
10.1042/CS20000299
ContentType Journal Article
Copyright 2004 S. Karger AG, Basel
Copyright 2004 S. Karger AG, Basel
Copyright_xml – notice: 2004 S. Karger AG, Basel
– notice: Copyright 2004 S. Karger AG, Basel
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
DOI 10.1159/000078313
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1423-0151
EndPage 190
ExternalDocumentID 10.1159/000078313
15181321
10_1159_000078313
78313
Genre Clinical Trial
Journal Article
GroupedDBID ---
0R~
0~B
30W
326
36B
3O.
3V.
4.4
53G
5GY
7X7
88E
8FI
8FJ
8UI
AAWTL
AAYIC
ABPAZ
ABUWG
ACGFS
ADAGL
ADBBV
AENEX
AEYAO
AFJJK
AFKRA
AHMBA
AIOBO
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZPMC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CYUIP
DIK
DU5
E0A
E3Z
EBS
EJD
EMB
EMOBN
F5P
FB.
FYUFA
GROUPED_DOAJ
HMCUK
HYE
HZ~
IAO
IHR
KUZGX
M--
M1P
MK0
O1H
O9-
OK1
P2P
PQQKQ
PROAC
PSQYO
RIG
RKO
RNS
RPM
RXVBD
SV3
TR2
UJ6
UKHRP
AAYXX
ABBTS
ABWCG
ACQXL
AFSIO
AHFRZ
CITATION
ITC
PHGZM
PHGZT
PJZUB
PPXIY
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c363t-23bcb05903f3ee83ddc0b680338f011082ee964c51c2bee6314ece9e81c4c9f23
IEDL.DBID UNPAY
ISSN 1011-7571
1423-0151
IngestDate Tue Aug 19 21:33:30 EDT 2025
Thu Sep 04 15:42:16 EDT 2025
Wed Feb 19 01:41:39 EST 2025
Wed Oct 01 06:30:46 EDT 2025
Thu Apr 24 23:05:01 EDT 2025
Thu Aug 29 12:04:28 EDT 2024
Thu Sep 05 17:58:24 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Glutathione peroxidase
Sodium selenite
Lymphedema
Head and neck cancer
Selenium
Radiotherapy
Endolaryngeal edema
Language English
License Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
https://www.karger.com/Services/SiteLicenses
Copyright 2004 S. Karger AG, Basel
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c363t-23bcb05903f3ee83ddc0b680338f011082ee964c51c2bee6314ece9e81c4c9f23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.karger.com/Article/Pdf/78313
PMID 15181321
PQID 71999392
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_71999392
crossref_citationtrail_10_1159_000078313
pubmed_primary_15181321
karger_primary_78313
unpaywall_primary_10_1159_000078313
crossref_primary_10_1159_000078313
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2004-01-01
PublicationDateYYYYMMDD 2004-01-01
PublicationDate_xml – month: 01
  year: 2004
  text: 2004-01-01
  day: 01
PublicationDecade 2000
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
PublicationTitle Medical principles and practice
PublicationTitleAlternate Med Princ Pract
PublicationYear 2004
References Whanger PD: Selenoprotein W: A review. Cell Mol Life Sci 2000;57:1846-1852.
Petrek JA, Pressman PI, Smith RA: Lymphedema: Current issues in research and management. CA Cancer J Clin 2000;50:292-307.
Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of lymphedema. Angiology 1999;50:189-192.
Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, Földi M, Gamble GL, Kasseroller RG, Leduc A, Lerner R, Mortimer PS, Norman SA, Plotkin CL, Rinehart-Ayres ME, Walder AL: American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998;83:2882-2885.987441710.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0
Földi E: Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998;18:2211-2212.
Weissleder H, Schuchardt C: Iatrogenic alteration of the lymphatic system; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 156-174.
Mücke R, Micke O, Schönekaes KG: Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2003;20:148.
Peters GM, Herbert WD: Reduction of edema in brain tumors by selenium application. Acta Neurol Pathol Oncol 1957;11:351-353.
Piller NB: Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990;53:209-218.2252630
Bruns F, Micke O, Bremer M: Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 2003;1:121-138.
Casley-Smith JR: Benzo-pyrones in the treatment of lymphoedema. Int Angiol 1999;18:31-41.
Loprinzi CL, Sloan J, Kugler J: Coumarin-induced hepatotoxicity. JCO 1997;15:3167-3168.
Beier A, Siems W, Brenke R, Grune T: Increased formation of free radicals in chronic lymphedema. Z Lymphol 1994;18:8-11.
Brenke R, Siems W: Adjuvant therapy in lymphedema. Z Lymphol 1996;20:31-35.
Casley-Smith JR, Gaffney RM: Excess plasma proteins as a cause of chronic inflammation and lymphodema: Quantitative electron microscopy. J Pathol 1981;133:243-272.7463213
Rockson SG: Lymphedema. Am J Med 2001;110:288-295.1123984710.1016/S0002-9343(00)00727-0
Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH: RTOG Late Effects Working Group. Overview. Late Effects on Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-1042.10.1016/0360-3016(95)00057-6
Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R: Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000;73:97-111.1104920310.1385/BTER:73:2:97
Rayman MP: The importance of selenium to human health. Lancet 2000;356:233-241.1096321210.1016/S0140-6736(00)02490-9
Johnson EW: Visual analog scale (VAS). Am J Phys Med Rehabil 2001;80:717.10.1097/00002060-200110000-00001
Herpertz U: Measuring and documentation of edema. Z Lymphol 1994;18:24-30.
Bahadur S, Amatya RC, Kacker SK: The enigma of post-radiation oedema and residual or recurrent carcinoma of the larynx and pyriform fossa. J Laryngol Otol 1985;99:763-765.
Megens A, Harris SR: Physical therapist management of lymphedema following treatment for breast cancer: A critical review of its effectiveness. Phys Ther 1998;78:1302-1311.
Ewald H: Radiotherapy of head and neck tumours and risk of lymphedema (in German). Z Lymphol 1996;20:21-26
Casley-Smith JR, Morgan RG, Piller NB: Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993;329:1158-1163.837777910.1056/NEJM199310143291604
Micke O, Bruns F, Schäfer U, Kisters K, Hesselmann S, Willich N: Selenium in the treatment of acute and chronic lymphedema. Trace Elem Electrolytes 2000;17:206-209.
Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H: Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 1998;46:731-738.10.1007/s001060050303
Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ: Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci (Lond) 2001;100:543-550.1129469510.1042/CS20000299
Földi E: The treatment of lymphedema. Cancer 1998;83:2833-2834.10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3
Kasseroller RG, Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: A review. Am J Ther 2000;7:273-279.
Obenheimer H, Jankowiak P, Berlemann K, Hermann V, Diethelm A: Clinical and biological effects of selenium in edema; in Gonzalez G (ed): Lymphedema: New Perspectives in Research and Treatment. Zaragossa, 1976.
Kasseroller R: Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998;18:2227-2230.
Schuchardt C, Pritschow H, Weissleder H: Conservative treatment; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 336-358.
Paskett ED, Stark N: Lymphedema: Knowledge, Treatment, and Impact among Breast Cancer Survivors. Breast J 2000;6:373-378.10.1046/j.1524-4741.2000.99072.x
Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, Plotkin J, Walker M: American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources-professional education and availability of patient services. Cancer 1998;83:2886-2887.10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M
Weissleder H, Schuchardt C: Lymphedema of the arm following breast cancer therapy; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 187-213.
Horvathova M, Jahnova E, Gazdik F: Effect of selenium supplementation in asthmatic subjects on the expression of endothelial cell adhesion molecules in culture. Biol Trace Elem Res 1999;69:15-26.
Schünemann H, Willich N: Lymphoedema of the arm after treatment of cancer of the breast: A study of 5868 cases. Dtsch Med Wochenschr 1997;122:536-541.
ref8
ref7
ref12
ref9
ref4
ref3
ref6
ref11
ref5
ref10
ref2
ref1
References_xml – reference: Schünemann H, Willich N: Lymphoedema of the arm after treatment of cancer of the breast: A study of 5868 cases. Dtsch Med Wochenschr 1997;122:536-541.
– reference: Herpertz U: Measuring and documentation of edema. Z Lymphol 1994;18:24-30.
– reference: Bruns F, Micke O, Bremer M: Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 2003;1:121-138.
– reference: Brenke R, Siems W: Adjuvant therapy in lymphedema. Z Lymphol 1996;20:31-35.
– reference: Obenheimer H, Jankowiak P, Berlemann K, Hermann V, Diethelm A: Clinical and biological effects of selenium in edema; in Gonzalez G (ed): Lymphedema: New Perspectives in Research and Treatment. Zaragossa, 1976.
– reference: Paskett ED, Stark N: Lymphedema: Knowledge, Treatment, and Impact among Breast Cancer Survivors. Breast J 2000;6:373-378.10.1046/j.1524-4741.2000.99072.x
– reference: Piller NB: Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990;53:209-218.2252630
– reference: Rockson SG: Lymphedema. Am J Med 2001;110:288-295.1123984710.1016/S0002-9343(00)00727-0
– reference: Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, Plotkin J, Walker M: American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources-professional education and availability of patient services. Cancer 1998;83:2886-2887.10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M
– reference: Bahadur S, Amatya RC, Kacker SK: The enigma of post-radiation oedema and residual or recurrent carcinoma of the larynx and pyriform fossa. J Laryngol Otol 1985;99:763-765.
– reference: Whanger PD: Selenoprotein W: A review. Cell Mol Life Sci 2000;57:1846-1852.
– reference: Johnson EW: Visual analog scale (VAS). Am J Phys Med Rehabil 2001;80:717.10.1097/00002060-200110000-00001
– reference: Rayman MP: The importance of selenium to human health. Lancet 2000;356:233-241.1096321210.1016/S0140-6736(00)02490-9
– reference: Kasseroller RG, Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: A review. Am J Ther 2000;7:273-279.
– reference: Beier A, Siems W, Brenke R, Grune T: Increased formation of free radicals in chronic lymphedema. Z Lymphol 1994;18:8-11.
– reference: Horvathova M, Jahnova E, Gazdik F: Effect of selenium supplementation in asthmatic subjects on the expression of endothelial cell adhesion molecules in culture. Biol Trace Elem Res 1999;69:15-26.
– reference: Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, Földi M, Gamble GL, Kasseroller RG, Leduc A, Lerner R, Mortimer PS, Norman SA, Plotkin CL, Rinehart-Ayres ME, Walder AL: American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998;83:2882-2885.987441710.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0
– reference: Micke O, Bruns F, Schäfer U, Kisters K, Hesselmann S, Willich N: Selenium in the treatment of acute and chronic lymphedema. Trace Elem Electrolytes 2000;17:206-209.
– reference: Weissleder H, Schuchardt C: Iatrogenic alteration of the lymphatic system; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 156-174.
– reference: Megens A, Harris SR: Physical therapist management of lymphedema following treatment for breast cancer: A critical review of its effectiveness. Phys Ther 1998;78:1302-1311.
– reference: Petrek JA, Pressman PI, Smith RA: Lymphedema: Current issues in research and management. CA Cancer J Clin 2000;50:292-307.
– reference: Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R: Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000;73:97-111.1104920310.1385/BTER:73:2:97
– reference: Weissleder H, Schuchardt C: Lymphedema of the arm following breast cancer therapy; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 187-213.
– reference: Casley-Smith JR: Benzo-pyrones in the treatment of lymphoedema. Int Angiol 1999;18:31-41.
– reference: Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH: RTOG Late Effects Working Group. Overview. Late Effects on Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-1042.10.1016/0360-3016(95)00057-6
– reference: Földi E: Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998;18:2211-2212.
– reference: Földi E: The treatment of lymphedema. Cancer 1998;83:2833-2834.10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3
– reference: Ewald H: Radiotherapy of head and neck tumours and risk of lymphedema (in German). Z Lymphol 1996;20:21-26
– reference: Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H: Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 1998;46:731-738.10.1007/s001060050303
– reference: Loprinzi CL, Sloan J, Kugler J: Coumarin-induced hepatotoxicity. JCO 1997;15:3167-3168.
– reference: Casley-Smith JR, Gaffney RM: Excess plasma proteins as a cause of chronic inflammation and lymphodema: Quantitative electron microscopy. J Pathol 1981;133:243-272.7463213
– reference: Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of lymphedema. Angiology 1999;50:189-192.
– reference: Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ: Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci (Lond) 2001;100:543-550.1129469510.1042/CS20000299
– reference: Kasseroller R: Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998;18:2227-2230.
– reference: Schuchardt C, Pritschow H, Weissleder H: Conservative treatment; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 336-358.
– reference: Peters GM, Herbert WD: Reduction of edema in brain tumors by selenium application. Acta Neurol Pathol Oncol 1957;11:351-353.
– reference: Mücke R, Micke O, Schönekaes KG: Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2003;20:148.
– reference: Casley-Smith JR, Morgan RG, Piller NB: Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993;329:1158-1163.837777910.1056/NEJM199310143291604
– ident: ref7
  doi: 10.1007/s001060050303
– ident: ref10
  doi: 10.1016/S0140-6736(00)02490-9
– ident: ref5
  doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2886::AID-CNCR46>3.0.CO;2-M
– ident: ref8
  doi: 10.1016/0360-3016(95)00057-6
– ident: ref1
  doi: 10.1016/S0002-9343(00)00727-0
– ident: ref6
  doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0
– ident: ref12
  doi: 10.1385/BTER:73:2:97
– ident: ref2
  doi: 10.1046/j.1524-4741.2000.99072.x
– ident: ref3
  doi: 10.1002/(SICI)1097-0142(19981215)83:12B+<2833::AID-CNCR35>3.0.CO;2-3
– ident: ref4
  doi: 10.1056/NEJM199310143291604
– ident: ref9
  doi: 10.1097/00002060-200110000-00001
– ident: ref11
  doi: 10.1042/CS20000299
SSID ssj0008330
Score 1.8319322
Snippet Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with...
To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery....
To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with...
SourceID unpaywall
proquest
pubmed
crossref
karger
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 185
SubjectTerms Aged
Chemotherapy, Adjuvant
Female
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - psychology
Head and Neck Neoplasms - radiotherapy
Humans
Lymphedema - drug therapy
Lymphedema - psychology
Lymphedema - radiotherapy
Male
Middle Aged
Original Paper
Quality of Life
Sodium Selenite - therapeutic use
Title Selenium in the Treatment of Head and Neck Lymphedema
URI https://karger.com/doi/10.1159/000078313
https://www.ncbi.nlm.nih.gov/pubmed/15181321
https://www.proquest.com/docview/71999392
https://www.karger.com/Article/Pdf/78313
UnpaywallVersion publishedVersion
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1423-0151
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0008330
  issn: 1423-0151
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-hDgF7GB8bLAyGBTzwkjW248R5nKZN5aNVJVZpPEX-uEhTu7SijdD467ETt4NpSHuL7Iuc-Gzd73zn3wF8pKhEUhkeK6plnGrq9pxA9yQ0y5m1Whp_33k4ygaT9MuFuAjnHcuQVjn1OdAtPWr_uJu-_thW_VxyX552K_OhpB5sTUbj4x9tMJPSOBedb-XQgfOOBQ0kQs5Yt_yM7bv_mJ6H3Sh3ActteNzUC3X9S81mfxmbs6cd89Gy5Sj0OSbTo2alj8zvWwyO9_mPZ7ATECcJfc_hAdYv4NEwxNR3QXz3lueyuSKXNXFwkJyvc8_JvCIDtwaIqi0ZoZmSb9dO-WjxSu3B5Oz0_GQQh2IKseEZX8WMa6P9TVNecUTJrTWJzmTiXNTKYwDJEIssNYIaphEzTlM0WKCkJjVFxfhL6NXzGveBSElVwg3LBdOpFKrgSltVGF4lRjn3KoJP63kuTWAa9wUvZmXrcYii3Kgkgvcb0UVHr3GX0G43lRuR0Hxwq3k4Hrc95cJWEbxbK7Z0O8aHQVSN82ZZ5p55wcHCCF51-r4ZWTi8wxmN4MNmAfz_s17fS-oAnnTJPv7U5g30Vj8bfOtwzEofOgT_-ethWMh_AFez7CU
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED9KOvbx0H1069yPVWx72IsbS7Js-bGMljCWEGgD3ZPRxxlKUicsMaX76yfZSraVDvpmpDOydRL3O93pdwCfKSqRVIbHimoZp5q6PSfQPQnNcmatlsbfdx6OssEk_XYlrsJ5xzKkVU59DnRLj9o_7aavP7ZVP5fcl6fdznwoqQfbk9H49EcbzKQ0zkXnWzl04LxjQQOJkDPWLT9j--4_pudJN8pDwPIFPGvqhbq7VbPZX8bm_GXHfLRsOQp9jsn0pFnpE_PrHoPjY_7jFewExElC32vYwvoNPB2GmPouiAtvea6bG3JdEwcHyeU695zMKzJwa4Co2pIRmin5fueUjxZv1FuYnJ9dfh3EoZhCbHjGVzHj2mh_05RXHFFya02iM5k4F7XyGEAyxCJLjaCGacSM0xQNFiipSU1RMf4OevW8xvdApKQq4YblgulUClVwpa0qDK8So5x7FcGX9TyXJjCN-4IXs7L1OERRblQSwceN6KKj13hIaLebyo1IaD641zwcj9uecmGrCI7Xii3djvFhEFXjvFmWuWdecLAwgr1O339GFg7vcEYj-LRZAP__rP1HSR3A8y7Zx5_aHEJv9bPBI4djVvpDWMK_AdRA6yw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selenium+in+the+Treatment+of+Head+and+Neck+Lymphedema&rft.jtitle=Medical+principles+and+practice&rft.au=Bruns%2C+F.&rft.au=B%C3%BCntzel%2C+J.&rft.au=M%C3%BCcke%2C+R.&rft.au=Sch%C3%B6nekaes%2C+K.&rft.date=2004-01-01&rft.issn=1011-7571&rft.eissn=1423-0151&rft.volume=13&rft.issue=4&rft.spage=185&rft.epage=190&rft_id=info:doi/10.1159%2F000078313&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000078313
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon